ONESOURCE SPECIALTY PHARMA LTD
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clini… Read more
ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) - Net Assets
Latest net assets as of September 2025: ₹59.04 Billion INR
Based on the latest financial reports, ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) has net assets worth ₹59.04 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹80.13 Billion) and total liabilities (₹21.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹59.04 Billion |
| % of Total Assets | 73.68% |
| Annual Growth Rate | 209.37% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 926.16 |
ONESOURCE SPECIALTY PHARMA LTD - Net Assets Trend (2023–2025)
This chart illustrates how ONESOURCE SPECIALTY PHARMA LTD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONESOURCE SPECIALTY PHARMA LTD (2023–2025)
The table below shows the annual net assets of ONESOURCE SPECIALTY PHARMA LTD from 2023 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹75.29 Billion | +1802.71% |
| 2024-03-31 | ₹3.96 Billion | -49.62% |
| 2023-03-31 | ₹7.85 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ONESOURCE SPECIALTY PHARMA LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 414900000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹114.43 Million | 0.19% |
| Other Components | ₹77.13 Billion | 131.15% |
| Total Equity | ₹58.81 Billion | 100.00% |
ONESOURCE SPECIALTY PHARMA LTD Competitors by Market Cap
The table below lists competitors of ONESOURCE SPECIALTY PHARMA LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MillerKnoll Inc
NASDAQ:MLKN
|
$1.21 Billion |
|
Lindsay Corporation
NYSE:LNN
|
$1.21 Billion |
|
Welspun Corp Limited
NSE:WELCORP
|
$1.21 Billion |
|
Dongguan Eontec Co Ltd
SHE:300328
|
$1.21 Billion |
|
Flow Traders Ltd.
PINK:FLTLF
|
$1.21 Billion |
|
Labrador Iron Ore Royalty Corporation
PINK:LIFZF
|
$1.21 Billion |
|
Enel Américas S.A
SN:ENELAM
|
$1.21 Billion |
|
Stx Heavy Indu
KO:071970
|
$1.21 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONESOURCE SPECIALTY PHARMA LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,957,130,000 to 58,805,790,000, a change of 54,848,660,000 (1386.1%).
- Net loss of 2,100,917 reduced equity.
- New share issuances of 8,755,230,000 increased equity.
- Other factors increased equity by 46,095,530,917.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-2.10 Million | -0.0% |
| Share Issuances | ₹8.76 Billion | +14.89% |
| Other Changes | ₹46.10 Billion | +78.39% |
| Total Change | ₹- | 1386.07% |
Book Value vs Market Value Analysis
This analysis compares ONESOURCE SPECIALTY PHARMA LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.65x to 2.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-03-31 | ₹68.64 | ₹1486.30 | x |
| 2024-03-31 | ₹34.58 | ₹1486.30 | x |
| 2025-03-31 | ₹532.66 | ₹1486.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ONESOURCE SPECIALTY PHARMA LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.01%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.28x
- Recent ROE (-0.00%) is above the historical average (-66.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -101.83% | -2066.00% | 0.02x | 2.56x | ₹-8.78 Billion |
| 2024 | -98.85% | -227.53% | 0.13x | 3.31x | ₹-4.31 Billion |
| 2025 | 0.00% | -0.01% | 0.19x | 1.28x | ₹-5.88 Billion |
Industry Comparison
This section compares ONESOURCE SPECIALTY PHARMA LTD's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $7,962,377,344
- Average return on equity (ROE) among peers: -6.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) | ₹59.04 Billion | -101.83% | 0.36x | $1.21 Billion |
| Anthem Biosciences Ltd (ANTHEM) | $17.41 Billion | 22.13% | 0.16x | $17.29 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $15.55 Million | -49.65% | 0.08x | $10.46 Million |
| Biocon Limited (BIOCON) | $14.77 Billion | 31.41% | 0.41x | $2.54 Billion |
| Blue Jet Healthcare Limited (BLUEJET) | $8.45 Billion | 19.37% | 0.25x | $134.93 Million |
| Concord Biotech Limited (CONCORDBIO) | $18.13 Billion | 20.50% | 0.12x | $346.78 Million |
| Dishman Carbogen Amcis Limited (DCAL) | $9.29 Billion | 6.11% | 1.42x | $103.76 Million |
| Haleos Labs Limited (HALEOSLABS) | $1.06 Billion | 16.78% | 1.56x | $129.20K |
| Lyka Labs Limited (LYKALABS) | $582.36 Million | -29.66% | 3.04x | $8.51 Million |
| Panacea Biotec Limited (PANACEABIO) | $1.96 Billion | -99.24% | 6.10x | $56.46 Million |